FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
18 oct. 2024 08h30 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development,...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
16 oct. 2024 09h15 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
11 oct. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
30 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Engages Southern Star Research as CRO in Australia
19 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Announces Filing of Patent Application for Generation of Functional Hematopoietic Organoids using Fibroblast Cell-Based Technology
12 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
06 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
20 août 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Files 2024 Second Quarter Report
07 août 2024 18h52 HE
|
Fibrobiologics, Inc.
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of...
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
15 juil. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...